Kalydeco: Medgend

Kalydeco FDA Approved Drugs

KALYDECO [Ivacaftor^{C₂₄H₂₈N₂O₃}]

150mg (oral tablet)

50mg/packet (oral granule)

75mg/packet (oral granule)

Vertex Pharms^{Jan 31, 2012}
Vertex Pharms Inc^{Mar 17, 2015}

Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
Method of treating cystic fibrosis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.